Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression [EXTENSION OF 700214990]

Trial Profile

Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression [EXTENSION OF 700214990]

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs Stapuldencel-T (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors SOTIO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 May 2017 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2015 Planned End Date changed from 1 Mar 2018 to 1 Apr 2017 as per ClinicalTrial.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top